1. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. WHO Guidelines Approved by the Guidelines Review Committee. Geneva2015.
2.Al Therwani S, Rosenbaek JB, Mose FH, Bech JN, Pedersen EB. Effect of tolvaptan on renal water and sodium excretion and blood pressure during nitric oxide inhibition: a dose-response study in healthy subjects. BMC nephrology. 2017;18(1):86.
3.Boeijen LL, Hoogeveen RC, Boonstra A, Lauer GM. Hepatitis B virus infection and the immune response: The big questions. Best practice & research Clinical gastroenterology. 2017;31(3):265–72.
4.Chuaypen N, Sriprapun M, Praianantathavorn K, et al. Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B[J]. J Med Virol, 2017, 89(1): 130–138.
5.Liem KS, van Campenhout MJH, Xie Q, et al. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B[J]. Aliment Pharmacol Ther, 2019, 49(4): 448–456.
6.Sonneveld MJ, Zoutendijk R, Hansen BE, Janssen HL. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir. Antiviral therapy. 2012;17(8):1605–8.
7.Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa–2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. The New England journal of medicine. 2004;351(12):1206–17.
8.Zhou J, Wu X, Wei W, You H, Jia J, Kong Y. A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B. International journal of environmental research and public health. 2016;13(5).
9.Vigano M, Invernizzi F, Grossi G, Lampertico P. Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection. Alimentary pharmacology & therapeutics. 2016;44(7):653–61.
10.Al Ashgar H, Peedikayil MC, Al Quaiz M, Al Sohaibani F, Al Fadda A, Khan MQ, et al. HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa–2a to ongoing tenofovir treatment: A randomized controlled study. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association. 2017;23(3):190-
11.Wei W, Wu Q, Zhou J, Kong Y, You H. A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis. International journal of environmental research and public health. 2015;12(8):10039–55.
12.Zeng W, Yuan J, Liu YX, Zhang Y, Li SX, Yao SM, et al. [Efficacy of Peg-interferon alpha–2a combinated with entecavir on HBeAg positive chronic hepatitis B patients with high serum hepatitis B viral loads]. Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology. 2013;27(2):115–8.
13.Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. Journal of gastroenterology. 2013;48(9):999–1005.
14.Matsumoto A, Nishiguchi S, Enomoto H, et al. Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy[J]. J Gastroenterol, 2018, 53(2): 247–257.
15.Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha–2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44(3):675–84.
16.Lampertico P. The royal wedding in chronic hepatitis B: The haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapy. Hepatology. 2015;61(5):1459–61.
17.Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M. Switching from entecavir to PegIFN alfa–2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). Journal of hepatology 2014; 61(4): 777–84.
18.Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, Jiang J, Xie Q, Dou X, Sun Y. O116: Predictive value of baseline and on-treatment qHBsAg level in HBeAg positive CHB patients who switched from NUCs to pegylated interferon A–2A: A further analysis from new switch study. Journal of hepatology 2015; 62: S251-S.
19.Hu P, Shang J, Zhang W, et al. HBsAg Loss with Peg-interferon Alfa–2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. Journal of clinical and translational hepatology, 2018, 6(1): 25–34.
20.Tang LSY, Covert E, Wilson E, et al. Chronic Hepatitis B Infection: A Review. Jama, 2018, 319(17): 1802–1813..
21.Ouzan D, Penaranda G, Joly H, Khiri H, Pironti A, Halfon P. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 2013;58(4):713–7.
22. Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY, Mao XN, Zou HH, Zhang WH. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrobial agents and chemotherapy 2015; 59(7): 4121–8.
23.Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, et al. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). Hepatology. 2015;61(5):1512–22.
24.Wang Y, Zhang Z, Ji D, Chen GF, Feng X, Gong LL, et al. Regulation of T cell function by microRNA–720. Scientific reports. 2015;5:12159.
25.Tachi Y, Hirai T, Ishizu Y, Honda T, Kuzuya T, Hayashi K, et al. alpha-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response. Journal of gastroenterology and hepatology. 2016;31(5):1001–8.
26.Bourliere M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, et al. Effect on HBs antigen clearance of addition of pegylated interferon alfa–2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. The lancet Gastroenterology & hepatology. 2017;2(3):177–88.
27.de Niet A, Jansen L, Stelma F, Willemse SB, Kuiken SD, Weijer S, et al. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial. The lancet Gastroenterology & hepatology. 2017;2(8):576–84.
28. Udompap P, Kim D, Ahmed A, et al. Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment[J]. Aliment Pharmacol Ther, 2018, 48(11–12): 1282–1289.